It also demonstrated that pharmacological inhibition or myeloid-specific ablation of HO-1 attenuates the occurrence of protumor events and enhances the effectiveness of specific anti-tumor immune responses and anti-PD-1-mediated immunotherapy. Here, HMOX1 is linked to neoplasm.